DRW Securities LLC Makes New Investment in Exelixis, Inc. (NASDAQ:EXEL)

DRW Securities LLC acquired a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 17,425 shares of the biotechnology company’s stock, valued at approximately $392,000.

Several other large investors have also recently made changes to their positions in EXEL. Renaissance Technologies LLC boosted its stake in Exelixis by 0.4% during the second quarter. Renaissance Technologies LLC now owns 15,163,066 shares of the biotechnology company’s stock valued at $340,714,000 after buying an additional 61,350 shares during the last quarter. LSV Asset Management raised its holdings in shares of Exelixis by 107.7% during the 2nd quarter. LSV Asset Management now owns 5,763,728 shares of the biotechnology company’s stock worth $129,511,000 after acquiring an additional 2,989,021 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Exelixis by 7.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 5,137,201 shares of the biotechnology company’s stock valued at $115,434,000 after acquiring an additional 349,837 shares during the last quarter. First Trust Advisors LP grew its holdings in shares of Exelixis by 18.5% in the fourth quarter. First Trust Advisors LP now owns 3,152,755 shares of the biotechnology company’s stock valued at $75,635,000 after purchasing an additional 492,613 shares in the last quarter. Finally, Norges Bank bought a new stake in Exelixis in the fourth quarter worth $73,449,000. 85.27% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, EVP Dana Aftab sold 95,000 shares of the stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $25.00, for a total transaction of $2,375,000.00. Following the transaction, the executive vice president now owns 520,990 shares of the company’s stock, valued at approximately $13,024,750. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, Director Maria C. Freire sold 8,250 shares of the company’s stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $26.56, for a total transaction of $219,120.00. Following the completion of the sale, the director now directly owns 91,007 shares in the company, valued at approximately $2,417,145.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Dana Aftab sold 95,000 shares of Exelixis stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $25.00, for a total value of $2,375,000.00. Following the completion of the transaction, the executive vice president now owns 520,990 shares in the company, valued at approximately $13,024,750. The disclosure for this sale can be found here. In the last ninety days, insiders sold 302,858 shares of company stock worth $7,980,629. 2.85% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Truist Financial reissued a “buy” rating and issued a $33.00 price objective (up from $32.00) on shares of Exelixis in a research note on Thursday, August 8th. UBS Group initiated coverage on Exelixis in a research report on Thursday, September 19th. They issued a “neutral” rating and a $30.00 price target for the company. StockNews.com upgraded Exelixis from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 13th. JMP Securities reiterated a “market outperform” rating and issued a $29.00 target price on shares of Exelixis in a report on Friday. Finally, HC Wainwright restated a “buy” rating and set a $29.00 price target on shares of Exelixis in a report on Wednesday, September 18th. Five research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Exelixis has an average rating of “Moderate Buy” and a consensus target price of $27.67.

Exelixis Price Performance

Shares of EXEL opened at $26.36 on Tuesday. The firm has a market capitalization of $7.99 billion, a price-to-earnings ratio of 41.19, a PEG ratio of 0.58 and a beta of 0.54. Exelixis, Inc. has a 1-year low of $18.64 and a 1-year high of $27.83. The company has a 50-day moving average of $25.28 and a 200 day moving average of $23.38.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.31 by $0.44. Exelixis had a net margin of 17.38% and a return on equity of 15.54%. The firm had revenue of $637.18 million during the quarter, compared to the consensus estimate of $468.21 million. On average, equities analysts anticipate that Exelixis, Inc. will post 1.54 earnings per share for the current fiscal year.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.